Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • EvaluatePharma
      • Evaluate Omnium
      • Japan Drug Forecasts
      • European Drug Forecasts
      • Epi Analyzer
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Trial Results

Thumbnail
January 21, 2021

Merck KGaA’s dual immuno-oncology weapon misfires

Bintrafusp alfa’s most important study, head to head against Keytruda in front-line lung cancer, is scrapped.

Thumbnail
January 19, 2021

Aclaris MK2 bears fruit

Aclaris takes a step towards an oral rheumatoid arthritis therapy.

Article image
Vantage logo
January 19, 2021

Biohaven pops the Alzheimer’s bubble

Troriluzole has failed in an Alzheimer’s trial, reminding the markets that this is par for the course in this disease.

Article image
Vantage logo
January 14, 2021

Nantkwest tries to catch the NK cell wave

Nantkwest claims efficacy with its most advanced NK cell therapy but, as ever with Patrick Soon-Shiong companies, it’s complicated.

Article image
Vantage logo
January 14, 2021

J&J provides early hope for single-dose Covid-19 vaccine

Pivotal data for JNJ-78436735 are imminent, with Novavax and Curevac not far behind.

Article image
Vantage logo
January 11, 2021

Lilly boosts biopharma with an early Alzheimer’s signal

Donanemab’s apparent success in a mid-stage trial can be read as support for the beta-amyloid hypothesis, but the reality is more complex.

Article image
Vantage logo
January 11, 2021

Pivotal valrox data give Biomarin déjà vu

Waning factor VIII levels mean the durability question is still unanswered.

Article image
Vantage logo
January 11, 2021

Sanofi makes a pre-JP Morgan splash with Kymab

The Kymab takeover represents another bold move as the French company bids to rebuild its pipeline.

Article image
Vantage logo
January 08, 2021

Gene therapy trial fails to rectify Sarepta’s sorry record

Sarepta’s first ever controlled study, of a Duchenne muscular dystrophy gene therapy, brings the markets down to earth.

Article image
Vantage logo
January 06, 2021

Mersana starts to lose its shine

The group’s latest data cut with XMT-1536 in ovarian cancer raises several red flags.

Article image
Vantage logo
January 05, 2021

Atyr’s Covid-19 benefit claims raise questions

The group has blamed placebo “overperformance” on a high proportion of less-sick patients.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

December 10, 2020

Evaluate Vantage 2021 Preview

July 29, 2020

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

View more...

Editor's Picks

Vantage logo
December 10, 2020

What the coming year might hold for biopharma

Vantage logo
December 11, 2020

Covid-19 vaccine developers remind the world that setbacks happen

Vantage logo
December 09, 2020

Astrazeneca’s vaccine looks increasingly like an also-ran

Vantage logo
November 09, 2020

Pfizer and Biontech snatch first Covid vaccine victory

Vantage logo
December 01, 2020

The promise and the perils of antigen testing

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.